CTAD 2022 Preview: Lecanemab Is Headliner After Gantenerumab’s Failure

Anti-Amyloid Debate Continues With Mixed Readouts

 
• By Mandy Jackson
Brain image on blue background
Lecanemab's efficacy may hinge on the type of amyloid it clears from the brain • Source: Shutterstock

More from Clinical Trials

More from R&D